Cover Image
市場調查報告書

類固醇荷爾蒙受體ERR1:開發平台分析

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 359831
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
類固醇荷爾蒙受體ERR1:開發平台分析 Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 25 Pages
簡介

本報告提供類固醇荷爾蒙受體ERR1 送交為標的的藥物適應症,開發階段,作用機制,給藥途徑及各分子類型分析,藥物的藥理作用之相關記述,並彙整迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

類固醇荷爾蒙受體ERR1的概要

治療藥的開發

類固醇荷爾蒙受體ERR1 :開發中的產品 - 各開發階段

類固醇荷爾蒙受體ERR1 :開發中的產品 - 治療範圍別

類固醇荷爾蒙受體ERR1 :開發中的產品 - 各適應症

類固醇荷爾蒙受體ERR1 :開發中產品概況

  • 初期階段的產品

類固醇荷爾蒙受體ERR1 :企業開發中的產品

類固醇荷爾蒙受體ERR1 :大學/機關開發中的產品

類固醇荷爾蒙受體ERR1 :治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

類固醇荷爾蒙受體ERR1的治療藥開發企業

  • Johnson & Johnson
  • Lead Pharma Holding B.V.

藥物簡介

類固醇荷爾蒙受體ERR1 :暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1011TDB

Summary:

According to the recently published report 'Steroid Hormone Receptor ERR1 - Pipeline Review, H2 2017'; Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Estrogen-related receptor alpha (ERRα) or Steroid hormone receptor ERR1 is a nuclear receptor that is encoded by the estrogen related receptor alpha (ESRRA) gene. ERRα regulates genes involved in mitochondrial biogenesis, gluconeogenesis, and fatty acid metabolism. ERRα acts as a transcriptional activator of CYP11B1 and CYP11B2 which indicates that this nuclear receptor may be required for the production of cortisol and aldosterone in the adrenal gland.

The report 'Steroid Hormone Receptor ERR1 - Pipeline Review, H2 2017' outlays comprehensive information on the Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Oncology which include indications Breast Cancer, Obesity, Type 2 Diabetes and Multiple Myeloma (Kahler Disease).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA)
  • The report reviews Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Overview
    • Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Companies Involved in Therapeutics Development
    • Lead Pharma Holding BV
  • Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Drug Profiles
    • CAS-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAS-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Estrogen Related Receptor Alpha for Metabolic Disorders and Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize ESRRA for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SR-16388 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Dormant Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Lead Pharma Holding BV, H2 2017
  • Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top